The latest price target for Biolase (OTCQB:BIOL) was reported by Ascendiant Capital on September 3, 2024. The analyst firm set a price target for $2.00 expecting BIOL to rise to within 12 months (a possible 3529.76% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biolase (OTCQB:BIOL) was provided by Ascendiant Capital, and Biolase maintained their buy rating.

There is no last upgrade for Biolase

There is no last downgrade for Biolase.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biolase, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biolase was filed on September 3, 2024 so you should expect the next rating to be made available sometime around September 3, 2025.

While ratings are subjective and will change, the latest Biolase (BIOL) rating was a maintained with a price target of $3.50 to $2.00. The current price Biolase (BIOL) is trading at is $0.06, which is out of the analyst’s predicted range.